Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets

Biochemical Pharmacology

Volumn 54, Issue 2, 1997, Pages 259-268

  Chang, Tong Shin ^a   Kim, Hyun Mee ^a   Lee, Ki Seon ^a   Khil, Lee Yong ^a   Mar, Woong Chon ^a   Ryu, Chung Kyu ^b   Moon, Chang Kiu ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

1,4 Naphthalenedione derivative; Aggregation; Platelet; Secretion; Thromboxane A2 receptor; Thromboxane A2 synthase

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; ANTITHROMBOCYTIC AGENT; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR; THROMBOXANE SYNTHASE; THROMBOXANE SYNTHASE INHIBITOR; CALCIUM; NAPHTHOQUINONE; NQ Y15; PROSTAGLANDIN SYNTHASE; SEROTONIN; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PLATELETS; CALCIUM; FEMALE; NAPHTHOQUINONES; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOXANE; SEROTONIN; THROMBOXANE A2; THROMBOXANE B2; THROMBOXANE-A SYNTHASE;

EID: 0030611418     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00179-2     Document Type: Article

References (56)

1. Mustard JF, Function of platelets and their role in thrombosis. Trans Am Clin Climatol Assoc 87: 104-127, 1976.
2. Bjorkerud SU, Mechanisms of atherosclerosis. Pathobiol Ann 9: 277-292, 1979.
3. Packham MA, The role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacol 72: 278-284, 1994.
4. Philip RB, Method of Testing Proposed Antithrombotic Drugs. CRC Press, Boca Raton, FL, 1981.
5. 2, and prostacyclin. Pharmacol Rev 30: 293-331, 1979.
6. 2 biosynthesis in human disease. Fedn Proc 46: 154-158, 1987.
7. 2 after low-dose aspirin. N Engl J Med 304: 76-79, 1981.
8. Gresele P, Deckmyn H, Nenci GG and Vermylen J, Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 12: 158-163, 1991.
9. 2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 157: 733-739, 1988.
10. 2 synthase inhibition alone and in combination: Comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol 102: 497-505, 1991.
11. 2 receptor blockade. J Pharmacol Exp Ther 266: 511-517, 1993.
12. Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O and Patrono C, A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis. J Pharmacol Exp Ther 269: 238-245, 1994.
13. 2 receptor antagonist in human platelets. Thromb Haemost 61: 479-484, 1989.
14. 2/prostaglandin endoperoxide receptor blockade combined in one molecule - I. Biochemical profile in vitro. Thromb Haemost 61: 35-42, 1989.
15. Anfossi G, Parisi S, Russo I, Mularoni EM, Massucco P, Cavalot F, Mattiello L and Trovati M, Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. Thromb Res 77: 399-410, 1995.
16. 2 production. Thromb Res 62: 717-724, 1991.
17. Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Goto F and Cacciatore L, Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 40: 880-885, 1989.
18. Neirotti M, Molaschi M, Ponzetto M, Macchione C, Poli L, Bonino F and Fabris F, Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Angiology 45: 137-141, 1994.
19. D'Andrea G, Perini F, Hasselmark L, Alecci M and Cananzi AR, Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. Funct Neurol 10: 91-98, 1995.
20. Hoet B, Arnout J, Van Geet C, Deckmyn H, Verhaeghe R and Vermylen J, Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma β-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemost 64: 87-90, 1990.
21. 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 89: 588-595, 1994.
22. Keith JC Jr, Endo Y, Warwick K, Keith KE, Brugh S and Rowles TK, Ridogrel improves maternal/fetal homeostasis in an ovine model of pregnancy-induced hypertension. Prostaglandins 47: 247-263, 1994.
23. Ryu CK, Synthesis of anticoagulant 2-chloro-3-(N-arylamino)-1,4-naphthoquinones. Yakhak Hoeji 32: 245-250, 1988.
24. Mustard JF, Perry DW, Ardlie NG and Packham MA, Preparation of suspensions of washed platelets from humans. Br J Haematol 22: 193-204, 1972.
25. Murphy CT, Elmore M, Kellie S and Westwick J, Comparison of the role of protein kinase C in platelet functional responses induced by three different mechanisms, PAF, ionomycin and arachidonic acid. Biochim Biophys Acta 1133: 46-54, 1991.
26. Holmsen H, Dangelmaier CA and Holmsen HK, Thrombin-induced platelet responses differ in requirement for receptor occupancy. Evidence for tight coupling of occupancy and compartmentalized phosphatidic acid formation. J Biol Chem 256: 9393-9396, 1981.
27. 2+ stores: Studies using fura-2. Biochem Biophys Res Commun 139: 308-314, 1986.
28. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260: 3440-3450, 1985.
29. 2 activity. Biochem J 294: 261-270, 1993.
30. 2. Biochim Biophys Acta 1083: 80-88, 1991.
31. Van Der Ouderaa FJ, Buytenhek M, Nugteren DH and Van Dorp DA, Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 487: 315-331, 1977.
32. Merino J, Livio M, Rajtar G and de Gaetano G, Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation. Biochem Pharmacol 29: 1093-1096, 1980.
33. Fitzpatrick FA and Gorman RR, A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid, two selective thromboxane synthetase inhibitors. Biochim Biophys Acta 539: 162-172, 1978.
34. 2 by the action of collagen on rat platelets. Thromb Res 46: 425-436, 1987.
35. Hwang DH, Species variation in platelet aggregation. In: The Platelets - Physiology and Pharmacology (Ed. Longenecker GL), pp. 289-305. Academic Press, New York, 1985.
36. Bult H and Bonta IL, Rat platelets aggregate in the absence of endogenous precursors of prostaglandin endoperoxides. Nature 264: 449-451, 1976.
37. 2 as an amplifying signal for other agonists. Am J Cardiol 68: 11B-15B, 1991.
38. 2 receptor interaction. J Pharmacol Exp Ther 228: 240-244, 1984.
39. Siess W, Siegel FL and Lapetina EG, Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J Biol Chem 258: 11236-11242, 1983.
40. Brass LF, Shaller CC and Belmonte EJ, Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin. J Clin Invest 79: 1269-1275, 1987.
41. 2 inhibitors. J Pharm Pharmacol 29: 222-228, 1977.
42. 2 in human platelets. Mol Pharmacol 16: 171-180, 1979.
43. 2 activity in human platelets stimulated with thrombin. Agents Actions 29: 364-373, 1990.
44. 2 isoforms. Activation by physiologic concentrations of calcium ion. J Biol Chem 261: 10467-10470, 1986.
45. 2 is not required for arachidonic acid liberation during platelet activation. Eur J Biochem 216: 169-175, 1993.
46. 2 which preferentially hydrolyzes an arachidonyl residue. FEBS Lett 282: 326-330, 1991.
47. 2 from bovine platelets. Biochem Biophys Res Commun 174: 189-196, 1991.
48. Pagels WR, Sachs RJ, Marnett LJ, Dewitt DL, Day JS and Smith WL, Immunochemical evidence for the involvement of prostaglandin H synthase in hydroperoxide-dependent oxidations by ram seminal vesicle microsomes. J Biol Chem 258: 6517-6523, 1983.
49. Smith WL, DeWitt DL, Shimokawa T, Kraemer SA and Meade EA, Molecular basis for the inhibition of prostanoid biosynthesis by nonsteroidal anti-inflammatory agents. Stroke 21: IV24-IV28, 1990.
50. Fitzpatrick FA, Ennis MD, Baze ME, Wynalda MA, McGee JE and Liggett WF, Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261: 15334-15338, 1986.
51. Ishikawa S, Manabe S and Wada O, Miconazole inhibition of platelet aggregation by inhibiting cyclooxygenase. Biochem Pharmacol 35: 1787-1792, 1986.
52. Ko FN, Lee YS, Wu TS and Teng CM, Inhibition of cyclooxygenase activity and increase in platelet cyclic AMP by girinimbine, isolated from Murraya Euchrestifolia. Biochem Pharmacol 48: 353-360, 1994.
53. 2 receptor antagonists. Biochem Pharmacol 37: 3923-3929, 1988.
54. Myou S, Fujimura M, Nishi K, Ohka T and Masuda T, Inhibitory effect of a selective thromboxane synthetase inhibitor, OKY-046, on acetaldehyde-induced bronchoconstriction in asthmatic patients. Chest 106: 1414-1418, 1994.
55. 2 synthase. Yakugaku Zasshi 114: 911-933, 1994.
56. Shikano M, Ito T, Ogawa K and Satake T, Effects of a selective thromboxane synthetase inhibitor (OKY-046) in patients with coronary artery disease during exercise. Adv Prostaglandin Thromboxane Leukot Res 13: 375-377, 1985.